Human ErbB3, Fc Tag (ER3-H5259) is expressed from human 293 cells (HEK293). It contains AA Ser 20 - Thr 643 (Accession # NP_001973.2).
Predicted N-terminus: Ser 20
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 95.4 kDa. The protein migrates as 130-140 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human ErbB3, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.
- (1) Singer, E. etal., 2001, J. Biol. Chem. 276 (47): 44266–74.
- (2) Kraus,M.H.etal.,1989,Proc.Natl.Acad.Sci.86:9193-9197.
- (3) Carraway,K.L.et al., 1994, J.Biol.Chem., 269: 14303-14306.
- (4) Wallasch,C.et al.,1995,EMBO.J.14:4267-4275.
- (5) Alimandi,M.et al.,1995,Oncogene.10:1813-1821.
- (6) Gamett,D.C.et al.,1995,J.Biol.Chem.270:19022-19027.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.